Cranbury, NJ, July 5, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of Glenn P. Sblendorio to its Board of Directors. Mr. Sblendorio will serve as the financial expert on the Board and will act as Chair of the audit committee. In addition, the company appointed Mark J. Simon as Senior Vice President of Business Development, promoted Douglas A. Branch to Vice President, General Counsel and Secretary, and hired Jayne Gershkowitz as Director, Public Policy.

"Amicus is pleased to welcome these four highly accomplished executives to our Board and management team," stated John F. Crowley, President and CEO of Amicus. "Their shared expertise and strong leadership skills will be invaluable as the Company continues its rapid growth and its development of new treatments for a range of human genetic diseases."

About Glenn Sblendorio

Mr. Sblendorio joins the Amicus Board of Directors as the financial expert and will act as Chair of the audit committee. He currently serves as the Chief Financial Officer and Executive Vice President for The Medicines Company. Prior to joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for The Medicines Company. From 1998 to July 2000, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio is also Chairman of NuLens Ltd., a medical device company that develops and manufactures intra-ocular lenses.

About Mark Simon

Mr. Simon joins the Amicus team as Senior Vice President of Business Development, after serving the Company as a consultant since February 2006. Mr. Simon has been serving as a consultant to multiple biopharmaceutical companies since October 2005. From 2002 to 2005, Mr. Simon served as Managing Director and Head of Life Sciences Investment Banking for Citigroup Global Markets. From 1988-2002, Mr. Simon served as a Senior Research Analyst and later as Managing Director, Investment Banking for Robertson Stephens.

About Douglas Branch

Mr. Branch has been promoted to the position of Vice President, General Counsel and Secretary after serving the company since December 2005 as General Counsel and Secretary. He also serves as President of Biotech Law Associates, P.C., a law firm representing emerging life science companies, and before founding that firm, he was a Director and Shareholder in Phillips McFall McCaffrey McVay & Murrah, P.C., an Oklahoma City law firm. He is the former Chairman of the Oklahoma Center for the Advancement of Science and Technology.

About Jayne Gershkowitz

Ms. Gershkowitz joined Amicus as Director, Public Policy after serving as National Executive Director of the National-Tay Sachs & Allied Diseases Association, Inc. (NTSAD), since 1998. Prior to NTSAD, Ms. Gershkowitz was Director of Marketing and Communications at Jewish Family & Children's Service of Greater Boston from 1991-1998. Ms. Gershkowitz recently held positions as Vice Chair of the Board of Directors of the National Organization for Rare Disorders, Vice Chair of the Management Council of the Global Organisation for Lysosomal Diseases, and is co-founder of the Lysosomal Storage Disease Research Consortium.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus is currently conducting Phase II clinical trials for its lead compound, Amigal™, for Fabry disease, and is conducting Phase I clinical trials of AT2101 for Gaucher disease. The company plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates," or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Amicus to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, Amicus claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. Amicus will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.